BioLineRx Ltd. Reports Q1 2025 Financial Results
Ticker: BLRX · Form: 6-K · Filed: May 27, 2025 · CIK: 1498403
Sentiment: neutral
Topics: financial-results, quarterly-report
TL;DR
BioLineRx dropped Q1 2025 earnings on May 27th. Check the financials.
AI Summary
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2025, on May 27, 2025. The company also published its unaudited interim consolidated financial statements and an operating and financial review as of the same date.
Why It Matters
This filing provides investors with an update on BioLineRx's financial performance and operational status for the first quarter of 2025, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new significant risks.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- March 31, 2025 (date) — Reporting period end date
- May 27, 2025 (date) — Date of press release and filing
FAQ
What is the reporting period for the financial results announced?
The financial results are for the three months ended March 31, 2025.
When were the financial results announced?
The financial results were announced on May 27, 2025.
What other documents were published along with the financial results?
The company also published its unaudited interim consolidated financial statements and its operating and financial review.
Does BioLineRx file annual reports under Form 20-F or Form 40-F?
BioLineRx files annual reports under Form 20-F.
What is the principal executive office address of BioLineRx Ltd.?
The principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 27, 2025 regarding BioLineRx Ltd. (BLRX).